Ruxolitinib Oxalate is a potent JAK1/JAK2 inhibitor belonging to the kinase inhibitor drug class, primarily indicated for the treatment of myelofibrosis and polycythemia vera by modulating cytokine signaling… Read more
Ruxolitinib Oxalate is a potent JAK1/JAK2 inhibitor belonging to the kinase inhibitor drug class, primarily indicated for the treatment of myelofibrosis and polycythemia vera by modulating cytokine signaling pathways. Laboratories rely on high-quality reference standards of this active pharmaceutical ingredient to ensure rigorous quality control and precise analytical testing. This collection supports the development and method validation of sensitive assays by providing essential materials for impurity profiling, including pharmacopeial and non-pharmacopeial impurities. Furthermore, the availability of stable isotope labelled compounds and identified metabolites enables accurate quantification and structural elucidation during pharmacokinetic studies. These comprehensive analytical tools are critical for verifying the purity and stability of the API throughout the drug development lifecycle, ensuring compliance with regulatory requirements for drug substance and product evaluation.